Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 8/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480453 | 0.85 | MTNR1B (0.56) | MTNR1BKMT2A | |
| SCHEMBL16465859 | 0.83 | ACE (0.56) | KEAP1NFE2L2ATML3MBTL1FABP7 | |
| SCHEMBL12489726 | 0.83 | KMT2A (0.41) | MTNR1BKEAP1ALDH1A1NPSR1KMT2A | |
| SCHEMBL8415675 | 0.83 | KMT2A (0.41) | MTNR1BKEAP1ALDH1A1NPSR1KMT2A | |
| SCHEMBL800088 | 0.83 | ACE (0.56) | KEAP1NFE2L2ATML3MBTL1FABP7 | |
| SCHEMBL3040971 | 0.83 | ACE (0.56) | KEAP1NFE2L2ATML3MBTL1FABP7 | |
| SCHEMBL3448995 | 0.79 | MTNR1B (0.49) | MTNR1BKMT2AACE | |
| SCHEMBL8218878 | 0.78 | ACE (0.42) | MTNR1BKEAP1ALDH1A1NPSR1KMT2A | |
| SCHEMBL3365554 | 0.78 | KMT2A (0.42) | KMT2AFABP7FABP5 | |
| SCHEMBL29397348 | 0.78 | KMT2A (0.42) | KMT2AFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060707-B2 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| US-20050090525-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1480971-A1 | ISOQUINOLINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074512-A1 | ISOQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090525-A1 | Isoquinoline derivatives | ITGB1, ITGB3, ITGA1 | MTNR1B 1726/4885KEAP1 3096/4885NFE2L2 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.